: iStockAnalyst.com Symbols Feed

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Takeover Investing: Profit From This Proven Warren Buffett Strategy

Tue, 06 Oct 2009 17:08:59 GMT

In 1964, Donald and Mildred Othmer placed $25,000 in the hands of a young Columbia University MBA graduate. In 1974, the graduate returned to offer them the choice of having their money back, or buying shares in his new company.[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

Three Dividend Plays That Can Offer Stability In The Face Of Uncertain Financial Markets

Thu, 21 May 2009 14:44:00 GMT

By Martin Biancuzzo Contributing Writer Money Morning As recently as February, General Electric Co. (NYSE: GE) had hopes of maintaining its dividend payout. "We’ve got... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

Discover The Best Ways To Invest Money In Real Estate

Tue, 03 Mar 2009 18:49:00 GMT

by Nick Cifonie Landing money to a business or organization with the trust of building additional wealth, apply money or attempt for future settlements, to grant, to install, to cover, to authorize, to put money into an enterprise with the expectation of profit can be describe as Investing. Investment is the assurance of something additional than money, time, energy or effort, a plan with the prospect of some valuable result, this job calls for the investment of some hard thinking. Investors contain be rushing to purchase gold as the financial disaster carry on to bite as a revenue of providing a safe continuing asset as other markets deteriorate. Gold actual value is not that it provided a rapid rough fix but that it obtainable a sure and stable means of caring wealth through investing. Model approach[More...]

Health Care Favorites For Long-Term Growth

Mon, 02 Mar 2009 14:08:00 GMT

"Long-time health-care investors can be forgiven their confusion; drug stocks are supposed to be defensive, but many of the largest drugmakers have been pounded," observes Richard Moroney. Nevertheless, in the blue chip Dow Theory Forecasts, the advisor sees two favorite health care issues as long-term opportunities: AstraZeneca (NYSE: [More...]

The Best Looking Chart In The Market

Thu, 19 Feb 2009 23:00:00 GMT

You are probably familiar with my colleague, Dr. Russell McDougal. He has been writing for Investor’s Daily Edge for more than two years, helping to alert our readers to the ongoing criminal activity of the “Axis of Weasels” in Washington. He has been sounding the alarm for years about the financial and monetary crisis that is now upon us. And for even longer, he has shouted from the rooftops about the ability of gold and silver to provide protection and profits in times like these. But you might not know how he came to be involved with Investor’s Daily Edge and what his background and experience are. I want to share that with you today. And there is a very good reason why you should listen. I firmly believe he can lead you to 200% to 300% gains this year… and thousands of percent upside in the years ahead. That’s a big promise in a very[More...]

Pharmaceuticals

Tue, 10 Feb 2009 18:38:00 GMT

Large pharmaceutical companies all seem to be in a similar boat heading into 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds as well. Revenue growth is non-existent, and earnings growth is being driven primarily by cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including Pfizer (PFE, 7x), Eli Lilly (LLY, 9x), Merck ([More...]

J&J: What Happened?

Wed, 21 Jan 2009 13:50:00 GMT

Johnson & Johnson reported fourth quarter earnings on Tuesday beating estimates and making many analysts who were once quite skeptical somewhat excited. However, shortly after the net income and EPS numbers came out, (JNJ: 56.75, 0.00 (0.00%)) lowered guidance. This understandably came during tough economic conditions (yes, even for a Healthcare giant like JNJ). Johnson & Johnson did have quite an exciting year, especially in the fourth quarter as they[More...]

JNJ's Disappointing Guidance

Tue, 20 Jan 2009 15:06:00 GMT

Johnson & Johnson (JNJ) reported fourth quarter 2008 financial results this morning. Revenue for the fourth quarter came in at $15.2 billion, about $1.0 billion below our forecast and down 5% from the same period in 2007. Much of the short-fall in revenues can be explained by foreign exchange, having a 4% negative impact on quarter for J&J. Operational growth declined by 1.0%. The Consumer, Pharmaceutical, and Medical Devices segments posted growth of 10.5%, (1.2%), and 6.4%, respectively in the quarter. The Consumer segment continues to benefit from the recent launch of OTC Zyrtec in the U.S. and the skin care business lead by Neutrogena and Aveeno. Pharmaceutical division sales were impacted by lower sales of Risperdal, now widely available as a[More...]

Johnson & Johnson 4Q profit rises 14 percent

Tue, 20 Jan 2009 19:57:00 GMT

TRENTON, N.J. - Health care products maker Johnson & Johnson on Tuesday posted a 14 percent increase in fourth-quarter profit, topping Wall Street forecasts, as big one-time gains offset slumping sales.
But the maker of baby shampoo, contraceptives and other health items forecast weaker results in 2009, blaming the global recession, unfavorable currency exchange rates and intensified pressure from both generic drugs and competitors' new products.
Still, its CEO said the economic uncertainty and J&J's strong cash flow - $12.2 billion in 2008 - put the company "in a great position" to acquire companies or products.

[More...]